Want to see SE:SUS full AI Analyst Report?

Surgical Science Sweden AB (SUS) Price & Analysis

5 Followers

SUS Stock Chart & Stats

kr52.10

kr0.26(0.80%)

At close: Jul 28 4:00 PM EDT

kr52.10

kr0.26(0.80%)

Day’s Range― - ―

52-Week Rangekr23.70 - kr94.40

Previous CloseN/A

Volume30.20K

Average Volume (3M)181.51K

Market Cap

kr2.82B

Enterprise Valuekr964.04M

Total Cash (Recent Filing)kr658.39M

Total Debt (Recent Filing)kr2.86M

Price to Earnings (P/E)30.2

Beta0.61

Next Earnings

Nov 12, 2026

EPS Estimate

0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.83

Shares Outstanding51,026,237

10 Day Avg. Volume123,849

30 Day Avg. Volume181,514

Financial Highlights & Ratios

PEG Ratio-0.50

Price to Book (P/B)0.39

Price to Sales (P/S)1.67

P/FCF Ratio24.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr45.00

Price Target Upside-13.63% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)2.06

Revenue Forecast (FY)kr986.87M

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetA debt-free balance sheet and substantial cash reserve give Surgical Science flexibility to fund production capacity, product development, and international expansion without relying heavily on external financing. This strengthens resilience through operating cycles and supports sustained investment in its growth platform.

Strong Revenue And License GrowthRapid license growth alongside double-digit quarterly revenue expansion indicates increasing adoption of the company’s software and training content. A larger recurring or repeatable content contribution can improve scalability, deepen customer relationships, and support a more durable revenue mix over time.

Margin And Operating ImprovementImproved gross margin and delivery of the 15% adjusted EBIT target show that pricing, mix, and operating initiatives are translating into stronger economics. Continued productivity from the Tel Aviv facility and cost discipline could help preserve profitability while the business expands.

Bears Say

Structural China HeadwindsPressure from government support for local Chinese manufacturers can constrain Surgical Science’s market access and growth in an important geography. Because management expects remediation to take multiple quarters, China may remain a structural drag on regional revenue and execution.

Profitability CompressionThe substantial decline in net and gross margins versus earlier periods indicates that recent growth has not translated consistently into prior levels of earnings quality. If lower profitability persists, it could reduce internal funding capacity and make future returns more dependent on renewed operating improvement.

Lumpy Revenue And Cash ConversionDependence on lumpy licenses and development projects creates timing uncertainty in reported revenue and earnings. Uneven conversion of profit into cash, together with volatile year-to-year free cash flow, can complicate planning, investment pacing, and assessment of the underlying earnings stream.

Surgical Science Sweden AB News

Surgical Science Sweden AB Earnings Call Signals Strength

Surgical Science Sweden AB (($SE:SUS)) has held its Q2 earnings call. Read on for the main highlights of...

2M ago

Surgical Science upgraded to Buy from Hold at Berenberg

Berenberg upgraded Surgical Science (SUSRF) to Buy from Hold with a SEK 45 price target The business is...

3M ago

Surgical Science Sweden AB Signals Resilient Underlying Growth

Surgical Science Sweden AB (($SE:SUS)) has held its Q1 earnings call. Read on for the main highlights of...

5M ago

Surgical Science Sweden Balances Record Quarter With 2026 Risk

Surgical Science Sweden AB (($SE:SUS)) has held its Q4 earnings call. Read on for the main highlights of...

8M ago

Surgical Science price target lowered to SEK 40 from SEK 120 at Berenberg

Berenberg analyst Simon Jonsson lowered the firm’s price target on Surgical Science (SUSRF) to SEK 40 from SEK...

11M ago

Surgical Science Sweden AB’s Mixed Q3 2025 Earnings Call

Surgical Science Sweden AB (($SE:SUS)) has held its Q3 earnings call. Read on for the main highlights of...

11M ago

SUS

SUS FAQ

What was Surgical Science Sweden AB’s price range in the past 12 months?

Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr94.40 in the past 12 months.

What is Surgical Science Sweden AB’s market cap?

Surgical Science Sweden AB’s market cap is kr2.82B.

When is Surgical Science Sweden AB’s upcoming earnings report date?

Surgical Science Sweden AB’s upcoming earnings report date is Nov 12, 2026 which is in 29 days.

How were Surgical Science Sweden AB’s earnings last quarter?

Surgical Science Sweden AB released its earnings results on Aug 19, 2026. The company reported kr0.41 earnings per share for the quarter, missing the consensus estimate of kr0.46 by -kr0.05.

Is Surgical Science Sweden AB overvalued?

According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Surgical Science Sweden AB pay dividends?

Surgical Science Sweden AB does not currently pay dividends.

What is Surgical Science Sweden AB’s EPS estimate?

Surgical Science Sweden AB’s EPS estimate is 0.68.

How many shares outstanding does Surgical Science Sweden AB have?

Surgical Science Sweden AB has 51,026,237 shares outstanding.

What happened to Surgical Science Sweden AB’s price movement after its last earnings report?

Surgical Science Sweden AB reported an EPS of kr0.41 in its last earnings report, missing expectations of kr0.46. Following the earnings report the stock price went up 24.706%.

Which hedge fund is a major shareholder of Surgical Science Sweden AB?

Currently, no hedge funds are holding shares in SE:SUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Surgical Science Sweden AB

Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.

Surgical Science Sweden AB (SUS) Earnings & Revenues

Historic Earnings Reports

SUS Stock 12 Month Forecast

Average Price Target

kr45.00

▼(-13.63% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"kr25","41":"kr41","57":"kr57","73":"kr73","89":"kr89"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,41,57,73,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.2,50.723076923076924,50.246153846153845,49.769230769230774,49.292307692307695,48.815384615384616,48.33846153846154,47.861538461538466,47.38461538461539,46.90769230769231,46.43076923076923,45.95384615384616,45.47692307692308,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.2,50.723076923076924,50.246153846153845,49.769230769230774,49.292307692307695,48.815384615384616,48.33846153846154,47.861538461538466,47.38461538461539,46.90769230769231,46.43076923076923,45.95384615384616,45.47692307692308,{"y":45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.2,50.723076923076924,50.246153846153845,49.769230769230774,49.292307692307695,48.815384615384616,48.33846153846154,47.861538461538466,47.38461538461539,46.90769230769231,46.43076923076923,45.95384615384616,45.47692307692308,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.1,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":84,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.3,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.92,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.82,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.2,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >